Endralazine
Chemical compound
- C02DB03 (WHO)
- 6-benzoyl-3-hydrazinyl-5H,6H,7H,8H-pyrido[4,3-c]pyridazine
- 39715-02-1 Y
- 47608
- 43316 N
- L44741F05P
- D08254 Y
- ChEMBL254193 N
- DTXSID40192791
- Interactive image
- c1ccc(cc1)C(=O)N2CCc3c(c/c(=N/N)/[nH]n3)C2
InChI
- InChI=1S/C14H15N5O/c15-16-13-8-11-9-19(7-6-12(11)17-18-13)14(20)10-4-2-1-3-5-10/h1-5,8H,6-7,9,15H2,(H,16,18) N
- Key:ALAXZYHFVBSJKZ-UHFFFAOYSA-N N
Endralazine is an antihypertensive of the hydrazinophthalazine chemical class.[1] It is not approved for use in the United States.
References
- ^ Meredith PA, Elliott HL, McSharry DR, Kelman AW, Reid JL (July 1983). "The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects". British Journal of Clinical Pharmacology. 16 (1): 27–32. doi:10.1111/j.1365-2125.1983.tb02139.x. PMC 1427948. PMID 6882620.
- v
- t
- e
Nonsympatholytic vasodilatory antihypertensives (C02)
- Hydralazine #
- Dihydralazine
- Endralazine
- Cadralazine
- Pildralazine
- see list
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e